Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency. Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial.
James L. Januzzi, Steven M. Snapinn, Peter M. DiBattiste, Ik-Kyung Jang, Pierre Theroux
Circulation. 2002;Originally published April 29, 2002
James L. Januzzi
Steven M. Snapinn
Peter M. DiBattiste